



MEDICAL DEVICES



PHARMACEUTICALS



CHEMICALS



FOOD & BEVERAGE



ELECTRONICS

*Available fo Immediate Delivery !*

# 2009-2018 **THREE ALTERNATIVE SCENARIOS** of The Future In Vitro Diagnostics Market

DESIGNED TO HELP INDUSTRY EXECUTIVES DEVELOP EFFECTIVE CONTINGENCY PLANS THAT BEST ACCOMMODATE UNCERTAINTIES AHEAD.

Scenario I: Business-As-Usual

Scenario II: Economic Austerity

Scenario III: Technological Breakthroughs

*Visit [www.vpgcorp.com](http://www.vpgcorp.com) to review this and over 5,000 other reports*



VENTURE PLANNING GROUP

[WWW.VPGCORP.COM](http://WWW.VPGCORP.COM)

INFORMATION • INTELLIGENCE • ANALYSIS • INSIGHT

# Table of Contents

## I. INTRODUCTION

## II. EXECUTIVE SUMMARY

### A. BUSINESS-AS-USUAL SCENARIO

### B. ECONOMIC AUSTERITY SCENARIO

### C. TECHNOLOGICAL BREAKTHROUGHS SCENARIO

## III. CONCLUSIONS AND RECOMMENDATIONS

## IV. THE SCENARIOS, 2008-2017

### A. BUSINESS-AS-USUAL SCENARIO

#### 1. Business Environment

##### a. Health Care Expenditures

##### b. Cost-Consciousness

##### c. Reimbursement

##### d. Industry Consolidation

##### e. Managed Care

###### • PPOs

###### • HMOs

##### f. Hospitals

##### g. Admissions

##### h. Length of Stay

##### i. Industry Diversification

##### j. Physician Demographics

##### k. Aging Population

###### • Chronic Illnesses

###### • Disease Incidence

###### • Susceptibility to Iatrogenesis

###### • Multiple Illness Cases

##### l. Laboratory Regulations

##### m. The FDA Reform

#### 2. Outlook for the In Vitro Diagnostics Market

##### a. Government Regulations

##### b. Centralized Testing

###### • Hospitals

###### • Commercial Laboratories

###### • Blood Banks

###### • Public Health Laboratories

##### c. Decentralized Testing

###### • Personal Testing

###### • Physician Offices/Group Practices

###### • Ancillary Hospital Locations

###### - ERs

###### - ORs

###### - ICUs/CCUs

###### • Cancer Clinics

###### • Ambulatory Care Centers

###### • Surgery Centers

###### • Nursing Homes

###### • Birth Centers

#### 3. Strategic Implications

##### a. Testing Patterns

###### • Test Utilization

###### • Pre-Admission Testing

###### • Inpatient Testing

###### • Outpatient Testing

#### 4. Market Segments

##### a. Chemistry and Immunoassay

###### • Introduction

###### • Future Situation

##### b. Microbiology and Serology

###### • Introduction

###### • Future Situation

##### c. Hematology and Flow Cytometry

###### • Introduction

###### • Future Situation

##### d. Histology and Cytology

###### • Introduction

###### • Future Situation

##### e. Coagulation

###### • Introduction

###### • Future Situation

##### f. Urinalysis

###### • Introduction

###### • Future Situation

##### g. Blood Banking

###### • Introduction

###### • Future Situation

#### 5. Technologies

##### a. Genomics

###### • Introduction

###### • Future Situation

##### b. Proteomics

###### • Introduction

###### • Future Situation

##### c. DNA Probes

###### • Introduction

###### • Future Situation

##### d. Biochips/Microarrays

###### • Introduction

###### • Future Situation

##### e. Monoclonal Antibodies

###### • Introduction

###### • Future Situation

##### f. Solid Phase Chemistry

###### • Introduction

###### • Future Situation

##### g. Biosensors

###### • Introduction

###### • Future Situation

##### h. Automation and Robotics

###### • Introduction

###### • Future Situation

##### i. Computer-Aided Diagnosis

###### • Introduction

###### • Future Situation

#### 6. The New Marketplace

##### a. Purchasing Influences

##### b. Marketing Strategies

##### c. Joint Ventures, Mergers and Licensing

##### d. Import-Export

##### e. Potential Market Entrants

##### f. Who May Not Survive?

## B. ECONOMIC AUSTERITY SCENARIO

### 1. Business Environment

#### a. Socio-Political Climate

##### • Cost-Consciousness

##### • Government Actions

##### • Three-Tier System

##### • Health Rationing

##### • Voucher System

##### • Health IRA

#### b. Hospital Closures

#### c. Hospital Utilization

#### d. Hospital Reorganization

#### e. Physician Regulations

#### f. Wellness Programs

#### g. Corporate Responses

#### h. Academic Research

### 2. Outlook for the In Vitro Diagnostics Market

#### a. Test Utilization

##### • Ordering Practices

##### • Documentation

##### • Recertification

#### b. Technology Regulations

#### c. New Laboratory Ventures

#### d. Computers

#### e. Industrial Medicine

#### f. Insurance Companies

#### g. Test Volume and Market Size

### 3. Strategic Implications

#### a. Testing Patterns

##### • Pre-Admission Testing

##### • Inpatient Testing

##### • Outpatient Testing

#### b. Market Segments

##### • Chemistry and Immunoassay

##### • Microbiology and Serology

##### • Hematology and Flow Cytometry

##### • Histology and Cytology

##### • Coagulation

##### • Urinalysis

##### • Blood Banking

#### c. Technologies

##### • Genomics

##### • Proteomics

##### • DNA Probes

##### • Biochips/Microarrays

##### • Monoclonal Antibodies and Immunoassays

##### • Automation and Robotics

##### • Solid Phase Chemistry

##### • Biosensors

##### • Computer-Aided Diagnosis

#### d. The New Marketplace

##### • Purchasing Influences

##### • Marketing Strategies

##### • Joint Ventures, Mergers and Licensing

##### • Import-Export

##### • Potential Market Entrants

##### • Who May Not Survive?

## C. TECHNOLOGICAL BREAKTHROUGHS SCENARIO

### 1. Business Environment

#### a. Political/Regulatory Climate

#### b. R & D Funding

#### c. Industry-Government Relationship

#### d. Industry-University Ventures

#### e. Technological Environment

#### f. Testing Decentralization

#### g. Health Care Expenditures

#### h. Physician Population

#### i. Hospital Indicators

### 2. Outlook for the In Vitro Diagnostics Market

#### a. Overview

#### b. Genomics

#### c. Proteomics

#### d. DNA and RNA Probes

#### e. Biochips/Microarrays

#### f. Monoclonal Antibodies

#### g. Immunoassays

#### h. Information Technology

#### i. Laboratory Automation and Robotics

#### j. Solid Phase Chemistry

#### k. Biosensors

#### l. Holography

#### m. Pharmaceuticals

### 3. Strategic Implications

#### a. Testing Patterns

##### • Pre-Admission Testing

##### • Inpatient Testing

##### • Outpatient Testing

##### • Test Volume and Market Size

#### b. Market Segments

##### • Chemistry and Immunoassay

##### • Microbiology and Serology

##### • Hematology and Flow Cytometry

##### • Histology and Cytology

##### • Coagulation

##### • Urinalysis

##### • Blood Banking

#### c. The New Marketplace

##### • Purchasing Influences

##### • Marketing Strategies

##### • Joint Ventures, Mergers and Licensing

##### • Import-Export

##### • Potential Market Entrants

##### • Who May Not Survive?

## V. APPENDICES: METHODOLOGY

### A. The Delphi

### B. Cross-Impact Analysis

### C. Substitution Modeling

# List of Tables

**Executive Summary Table I:** Business-As-Usual Scenario, Growth Areas in Clinical Laboratory Testing, 2008-2018

**Executive Summary Table II:** Economic Austerity Scenario, Growth Areas in Clinical Laboratory Testing, 2008-2018

**Executive Summary Table III:** Technological Breakthroughs Scenario, Growth Areas in Clinical Laboratory Testing, 2008-2018

**Executive Summary Table IV:** Market Size by Location

**Executive Summary Table V:** Market Size by Laboratory Discipline

**Table-1:** Business-As-Usual Scenario, Health Care Costs by Expenditure Type

**Table-2:** Business-As-Usual Scenario, HMO and PPO Enrollment

**Table-3:** Business-As-Usual Scenario, Selected Hospital Statistics

**Table-4:** Business-As-Usual Scenario, Total Population and Physician Demographics

**Table-5:** Business-As-Usual Scenario, Test Volume by Location

**Table-6:** Business-As-Usual Scenario, Test Distribution by Location

**Table-7:** Business-As-Usual Scenario, Market Size by Location

**Table-8:** Business-As-Usual Scenario, Typical Pre-Admission Tests

**Table-9:** Business-As-Usual Scenario, Test Volume by Laboratory Discipline

**Table-10:** Business-As-Usual Scenario, Market Size By Laboratory Discipline

**Table-11:** Economic Austerity Scenario, Selected Hospital Statistics

**Table-12:** Economic Austerity Scenario, HMO and PPO Enrollment

**Table-13:** Economic Austerity Scenario, Total Population and Physician Demographics

**Table-14:** Economic Austerity Scenario, Major Categories of Overutilized Tests

**Table-15:** Economic Austerity Scenario, Test Volume by Location

**Table-16:** Economic Austerity Scenario, Test Distribution by Location

**Table-17:** Economic Austerity Scenario, Market Size by Location

**Table-18:** Economic Austerity Scenario, Timing Requirements for Selected Laboratory Tests

**Table-19:** Economic Austerity Scenario, Test Volume by Laboratory Discipline

**Table-20:** Economic Austerity Scenario, Market Size by Laboratory Discipline

**Table-21:** Technological Breakthroughs Scenario, HMO and PPO Enrollment

**Table-22:** Technological Breakthroughs Scenario, Total Population and Physician Demographics

**Table-23:** Technological Breakthroughs Scenario, Selected Hospital Statistics

**Table-24:** Technological Breakthroughs Scenario, Test Volume by Location

**Table-25:** Technological Breakthroughs Scenario, Test Distribution by Location

**Table-26:** Technological Breakthroughs Scenario, Market Size by Location

**Table-27:** Technological Breakthroughs Scenario, Test Volume by Laboratory Discipline

**Table-28:** Technological Breakthroughs Scenario, Market Size by Laboratory Discipline

# ORDER FORM

TO: VENTURE PLANNING GROUP

545 Eighth Avenue • Suite 401 • New York • NY • 10018 tel. 212.564.2838 fax. 212.564.8133 info@vpgcorp.com

I am interested in your new study:

**“Three Alternative Scenarios Of The Future In Vitro Diagnostics Market”**

I am interested in your new report:

	Before November 27, 2009	After November 27, 2009
<input type="checkbox"/> PDF .....	\$9,800 .....	\$11,800
<input type="checkbox"/> Print .....	8,200 .....	9,700
<input type="checkbox"/> Both .....	12,600 .....	15,100

name:	title:
company:	
address:	
city:	state:
zip:	country:
telephone:	fax:
email:	

## Payment Options

Check payable to Venture Planning Group     Please send me an invoice     Please charge my credit card

card type:  Visa     MasterCard     AMEX     Other

cardholder's name:

card number:

expiration date:

signature:



WWW.VPGCORP.COM